Making the information on the use of biosimilars in the National Health System transparent is essential to be able to evaluate the policies to promote these drugs in hospitals and CCs. AA. This article, published in the Gaceta Médica Yearbook, outlines various lines of improvement consistent with the Pharmaceutical Strategy for Europe.